Alector to Participate in Upcoming Healthcare Conferences
Alector to Participate in Upcoming Healthcare Conferences
Alector Contacts: SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in the following upcoming investor conferences:
加利福尼亞州南舊金山，2024年5月9日（GLOBE NEWSWIRE）——開創免疫神經病學的臨床階段生物技術公司Alector, Inc.（納斯達克股票代碼：ALEC）今天宣佈，管理層將參加以下即將舉行的投資者會議：
- Bank of America Securities Health Care Conference (Las Vegas, Nevada)
- Tuesday, May 14, 2024, at 8:55 a.m. PT, corporate presentation
- H.C. Wainwright 2nd Annual BioConnect Investor Conference (New York, New York)
- Monday, May 20, 2024, at 11:00 a.m. ET, fireside chat
- 美國銀行證券醫療保健會議（內華達州拉斯維加斯）
- 太平洋時間 2024 年 5 月 14 日星期二上午 8:55，企業演講
- H.C. Wainwright 2和 年度BioConnect投資者大會（紐約、紐約）
- 美國東部時間 2024 年 5 月 20 日星期一上午 11:00，爐邊談話
A webcast of each conference presentation will be available on the "Events & Presentations" page within the Investors section of the Alector website at Replays of the webcasts will be available on the Alector website for 90 days following the presentation dates.
每場會議演講的網絡直播將在Alector網站投資者部分的 “活動與演講” 頁面上提供。網絡直播的重播將在演講日期後的90天內在Alector網站上播出。
About Alector
Alector is a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. Alector has discovered and is developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brain's immune system and enable rejuvenated immune cells to counteract emerging brain pathologies. Alector's immuno-neurology product candidates are supported by biomarkers and seek to treat indications, including Alzheimer's disease and genetically defined frontotemporal dementia patient populations. Alector is headquartered in South San Francisco, California.
關於 Alector
Alector是一家臨床階段的生物技術公司，開創了免疫神經病學，這是一種治療神經退行性疾病的新型治療方法。免疫神經病學將免疫功能障礙作爲多種疾病的根本原因，這些疾病是退行性腦疾病的驅動因素。Alector已經發現並正在開發廣泛的先天免疫系統計劃，這些計劃旨在功能修復導致大腦免疫系統功能障礙的基因突變，並使恢復活力的免疫細胞能夠抵消新出現的大腦疾病。Alector的免疫神經病學候選產品得到生物標誌物的支持，旨在治療適應症，包括阿爾茨海默氏病和基因定義的額瞼癡呆患者群體。Alector 總部位於加利福尼亞州南舊金山。
Alector Contacts:
Alector
Katie Hogan
202-549-0557
katie.hogan@alector.com
Alector 聯繫方式：
亞歷克託
凱蒂·霍根
202-549-0557
katie.hogan@alector.com
1AB (media)
Dan Budwick
973-271-6085
dan@1abmedia.com
1AB（媒體）
丹·佈德威克
973-271-6085
dan@1abmedia.com
Argot Partners (investors)
Laura Perry
212.600.1902
alector@argotpartners.com
Argot 合夥人（投資者）
勞拉·佩裏
212.600.1902
alector@argotpartners.com
譯文內容由第三人軟體翻譯。